• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Step Therapy Requirements Are Worsening, Says Dr James Howard

Video

Myasthenia gravis expert James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the burdens that step therapy places on patients with rare diseases and their providers.

James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, former chief of the Neuromuscular Disorders Division, and former James F. Howard Distinguished Professor of Neuromuscular Disease, explains the step therapy burdens faced by patients with myasthenia gravis, as well as their providers.

Transcript

How are patients with rare diseases like myasthenia gravis affected by step therapy and prior authorization, and do you see this getting better or worse?

The burdens that are placed on to us by our payers through prior authorizations, etc, are overly burdensome. It consumes time—not only the physician, but of the staff—to complete paperwork, to spend countless amounts of time on telephone calls that totally detracts from our ability to provide top-level care to the individual patient themselves. I foresee this, unless there's a change in culture, in our legislature, I see this becoming progressively worse. And it has been over my career.

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Sarah Bajorek, PhD, BCACP, MBA.
Pat Van Burkleo
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
dr lawrence eichenfield
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.